Fig. 8

ALS-associated genes regulated by GM6. (a) ALS-associated genes (3+ database sources) overlap with GM6-increased/decreased genes (FDR < 0.10). (b) ALS-associated genes (2 database sources) overlap with GM6-increased/decreased genes (FDR < 0.10). (c) ALS-associated genes (1 database source) overlap with GM6-increased/decreased genes (FDR < 0.10). In (a) – (c), GM6-increased genes include those increased by GM6 with respect to any of the 4 differential expression analyses (6, 24, 48, and/or 6–48 h; FDR < 0.10), and GM6-decreased genes include those decreased by GM6 with respect to any of the 4 differential expression analyses (6, 24, 48, and/or 6–48 h; FDR < 0.10). (d) ALS-associated genes (3+ sources). (E) ALS-associated genes (2 sources). (f) ALS-associated genes (1 source). In (D) – (f), heatmaps show the ALS-associated genes most consistently altered by GM6 (6–48 h). (g) ATP binding cassette subfamily G member 1 (ABCG1) expression. (h) Neurofilament light (NEFL) expression. (i) Neural precursor cell expressed developmentally down-regulated 4-like E3 ubiquitin protein ligase (NEDD4L) expression. In (g) – (i), letters shown for each bar indicate results from post hoc treatment comparisons (Fisher’s least significant difference), where treatments not sharing the same letter differ significantly (P < 0.05). (j) Gene symbol cloud for ALS-associated genes (3+ sources). (k) Gene symbol cloud for ALS-associated genes (2 sources). (l) Gene symbol cloud for ALS-associated genes (1 source). In (j) – (l), the size of each symbol corresponds to the significance of p-values across the three time points (6, 24 and 48 h; red = GM6-increased; blue = GM6-decreased)